Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Rational Analyst -- Ignore unavailable to you. Want to Upgrade?

To: Susan Saline who wrote (1022)	5/28/1998 2:59:00 PM
From: Scott H. Davis	Respond to of 1720

[Reply to Susan on biotech post questions] Sorry Susan, I did not review that post before I posted. ASHP is American Society for Health-system Pharmacists, AJHP is American Journal of Health-system Pharmacy. Also, I omitted a couple things. First a snippet from a TTNP thread <<Now to the more current potential for TTNP's stock. TTNP's lead product is ILOPERIDONE, a proprietary oral antipsychotic drug licensed from Hoechst Marion Roussel, for the treatment of schizophrenia and related psychotic disorders. ILOPEODONE treats both positive and negative schizophrenic symptoms, and has less side effects as indicate in Phase II trials. They are now moving into PHASE III trials which will last six weeks. These results are expected in the first quarter of 1999 with an FDA approval by mid-1999. Novartis, one of the world's largest drug companies must feel very positive about ILOPERIDONE, as they have signed a deal with TTNP to market the drug worldwide (excluding Japan), with an upfront payment of $23 Million, $15 million in milestone payments with an NDA filing and approval, and then pay TTNP royalty payments probably in the 10% range. Additionally, Novartis has agreed to fund the extensive Phase III trials. The market for such a drug will be in the order of $4 Billion by 2000.>> There's a promissing Parkinsons therapy, (pre-clinical) biz.yahoo.com Plus the cancer vaccines biz.yahoo.com Sharing this as a possibility - I have not researched enough to buy let alone recomend, but it remains interesting. Scott BTW, thanks for the "creativity response" (I actually was an art major first 2 years at ISU)